Peptomyc focuses on the development of a new generation of cell-penetrating peptides targeting the Myconcoprotein for cancer treatment.
Peptomyc has raised $5.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2026.
Peptomyc's investors include European Innovation Council, European Commission, Centre for the Development of Industrial Technology (CDTI), EISMEA, Horizon 2020.
Peptomyc is headquartered in Barcelona, Spain.
Peptomyc focuses on the development of a new generation of cell-penetrating peptides targeting the Myconcoprotein for cancer treatment.
Peptomyc is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Peptomyc — Funding & Investors." VCBacked, March 24, 2026, https://www.vcbacked.co/company/peptomyc. Accessed August 15, 2026.
VCBacked. (2026). Peptomyc — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/peptomyc
{{cite web |title=Peptomyc — Funding & Investors |url=https://www.vcbacked.co/company/peptomyc |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated